AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

Trixeo Aerosphere is an inhalation treatment for chronic obstructive pulmonary disease (COPD) and contains a triple combination of budesonide, formoterol, and glycopyrronium. The treatment has previously been approved in a large number of countries for COPD using the propellant HFA-134a.

When HFA-134a was introduced, it served as an alternative to older propellants that contained chlorine and could damage the ozone layer. HFA-134a does not harm the ozone layer, but it has a Global Warming Potential (GWP) of 1430. GWP is a measure of how much a greenhouse gas contributes to global warming compared to carbon dioxide.